InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Share Price

Current share price for VFY : $2.250 0.11 (4.66%)+

Vitrafy Life Sciences Limited (VFY) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems.

VFY General Information +

ASX Code VFY
Website http://www.vitrafy.com
Industry/Sector Life Sciences Tools & Services
Market Cap ($M) 140
VFY Share Price $2.250
Day High $2.460
Day Low $2.250
Last Close $2.360
VFY Share Price Movement $0.11 ( 4.66% )
Prices as at 16:40, 29 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Vitrafy Life Sciences Limited (VFY) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Vitrafy Life Sciences Limited (VFY) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Vitrafy Life Sciences Limited (VFY) price-sensitive announcements

VFY - Q1 FY27 Quarterly Activities Report and Appendix 4C
Vitrafy Life Sciences Limited’s Q1 FY27 Quarterly Activities Report and Appendix 4C for th
Vitrafy Life Sciences Limited (VFY)
28 Oct 2026 | 8:17 AM
VFY - Vitrafy enters partnership with Versiti Blood Health
Vitrafy Life Sciences Limited announced a partnership with Versiti Blood Health, a U.S. no
Vitrafy Life Sciences Limited (VFY)
30 Sep 2026 | 12:02 PM
VFY - S&P DJI Announces September 2026 Quarterly Rebalance
S&P Dow Jones Indices announced on 4 September 2026 its September 2026 quarterly rebalance
Vitrafy Life Sciences Limited (VFY)
4 Sep 2026 | 5:10 PM
VFY - Vitrafy enters U.S. Cell & Gene Therapy Market
Vitrafy Life Sciences Limited announced that it has entered the U.S. cell and gene therapy
Vitrafy Life Sciences Limited (VFY)
2 Sep 2026 | 9:17 AM

Vitrafy Life Sciences Limited (VFY) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 Quarterly Investor Briefing Presentation 28 Oct 2026 8:17AM $2.410 $2.250 fallen by 6.64%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 Q1 FY27 Quarterly Activities Report and Appendix 4C 28 Oct 2026 8:17AM $2.410 $2.250 fallen by 6.64%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 Vitrafy Q1 FY27 Investor Briefing 26 Oct 2026 1:49PM $2.480 $2.250 fallen by 9.27%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 Application for quotation of securities - VFY 20 Oct 2026 9:10AM $2.710 $2.250 fallen by 16.97%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 Appointment of Chief Financial Officer 20 Oct 2026 8:24AM $2.710 $2.250 fallen by 16.97%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
 Health Care $140 2026 Notice of Annual General Meeting 16 Oct 2026 8:22AM $2.870 $2.250 fallen by 21.60%

VFY Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$16.17 -$25.20 -65.50% 0.00 0.00 0.00% 0.0%
2025A -$32.71 -$73.00 347.20% 0.00 0.00 0.00% 0.0%
2024A -$10.43 -$16.30 33.40% 0.00 0.00 0.00% 0.0%

VFY Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Vitrafy Life Sciences Limited (VFY) $150M -0.6552 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

VFY Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.33 0.00
Market 0.30 13.30 1.03 0.73
Sector 0.77 37.50 2.28 2.04

VFY Directors

Name Position Start Date
Mr Brent Michael Leslie Owens Chief Executive Officer, Managing Director 29 Mar 2018
Ms Kathryn(Kate) Marian Munnings Non-Executive Director 10 Oct 2024
Mr Vaughan Webber Non-Executive Director 30 Nov 2022
Dr Jeannie(Jeannette) Joughin Non-Executive Director 20 Jan 2026
Dr Leigh Bernard Farrell Non-Executive Director, Non-Executive Chairman 16 Oct 2025

Vitrafy Life Sciences Limited (VFY) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
9 Jul 2026 WEBBER, Vaughan Buy Indirect Shares 2,454 $2.600 $6,380.400
9 Jul 2026 OWENS, Brent Buy Indirect Shares 1,636 $2.600 $4,253.600
9 Jul 2026 MUNNINGS, Kathryn(Kate) Buy Indirect Shares 2,454 $2.600 $6,380.400

See all changes in directors' interest & trades for Vitrafy Life Sciences Limited (VFY) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

VFY Management

Name Position
Simon Martin Chief Financial Officer
Michael Sapountzis Company Secretary

VFY Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vitrafy Life Sciences Limited (VFY). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
4,825,839 (7.56%) Ryder Capital Limted and associated entities

VFY Calendar of Events

Date Event
03 August 2027 Report (Annual)
03 August 2027 Report (Prelim)
03 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.